All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said Takeda Development Center Shanghai and Takeda Development Center Asia Pte. Ltd., started the Phase III TOURMALINE-MM1 global study with the oral proteasome inhibitor, ixazomib, in relapsed and/or refractory multiple myeloma.